BELITE BIO, INC
BELITE BIO, INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Pharmaceutical Preparations.
The next scheduled catalyst is Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy on June 30, 2027. There are 2 upcoming events on record.
Cash runway is approximately 114.5 months based on the most recent reported cash position and quarterly operating burn as of 2025-12-31.
| Date | Event | Type | Phase |
|---|---|---|---|
| June 30, 2027 | Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy | Trial Milestone | Phase 3 |
| February 15, 2028 | A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease | Trial Milestone | Phase 2/Phase 3 |
Track BLTE alongside other companies. Add it to a watchlist and see every catalyst on one calendar.
Open BLTE in the trackerTrial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.
Last updated 2026-10-14.